Abstract
Oxidative stress is an imbalance between cellular production of reactive oxygen species and the counteracting antioxidant mechanisms. The brain with its high oxygen consumption and a lipid-rich environment is considered highly susceptible to oxidative stress or redox imbalances. Therefore, the fact that oxidative stress is implicated in several mental disorders including depression, anxiety disorders, schizophrenia and bipolar disorder, is not surprising. Although several elegant studies have established a link between oxidative stress and psychiatric disorders, the causal relationship between oxidative stress and psychiatric diseases is not fully determined. Another critical aspect that needs much attention and effort is our understanding of the association between cellular oxidative stress and emotional stress. This review examines some of the recent discoveries that link oxidative status with anxiety, depression, schizophrenia and bipolar disorder. A discussion of published results and questions that currently exist in the field regarding a causal relationship between oxidative and emotional stress is also provided.
Keywords: Anxiety, depression, oxidative stress, psychological stress.
Current Neuropharmacology
Title:Oxidative Stress and Psychological Disorders
Volume: 12 Issue: 2
Author(s): Samina Salim
Affiliation:
Keywords: Anxiety, depression, oxidative stress, psychological stress.
Abstract: Oxidative stress is an imbalance between cellular production of reactive oxygen species and the counteracting antioxidant mechanisms. The brain with its high oxygen consumption and a lipid-rich environment is considered highly susceptible to oxidative stress or redox imbalances. Therefore, the fact that oxidative stress is implicated in several mental disorders including depression, anxiety disorders, schizophrenia and bipolar disorder, is not surprising. Although several elegant studies have established a link between oxidative stress and psychiatric disorders, the causal relationship between oxidative stress and psychiatric diseases is not fully determined. Another critical aspect that needs much attention and effort is our understanding of the association between cellular oxidative stress and emotional stress. This review examines some of the recent discoveries that link oxidative status with anxiety, depression, schizophrenia and bipolar disorder. A discussion of published results and questions that currently exist in the field regarding a causal relationship between oxidative and emotional stress is also provided.
Export Options
About this article
Cite this article as:
Salim Samina, Oxidative Stress and Psychological Disorders, Current Neuropharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/1570159X11666131120230309
DOI https://dx.doi.org/10.2174/1570159X11666131120230309 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets NOS: Molecular Mechanisms, Clinical Aspects, Therapeutic and Monitoring Approaches
Current Drug Targets - Inflammation & Allergy Gene Therapy for Neurological Disorders: Challenges and Future Prospects for the Use of Growth Factors for the Treatment of Parkinsons Disease
Current Gene Therapy The Immune System and the Brain: Crosstalk with a Broad Impact From Host Defense to Cognition
Current Neurovascular Research Partial Dopamine Agonists and Dopaminergic Stabilizers, in the Treatment of Psychosis
Current Drug Targets - CNS & Neurological Disorders Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design Domperidone in Parkinson’s Disease: A Perilous Arrhythmogenic or the Gold Standard?
Current Drug Safety Risperidone Long-Acting Injection in the Treatment of First Episode Schizophrenia
Current Psychopharmacology The Endocannabinoid System in Parkinsons Disease
Current Pharmaceutical Design Non-Analgesic Effects of Opioids: Interactions Between Opioids and Other Drugs
Current Pharmaceutical Design Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pathological Gambling in Parkinson’s Disease: An Update on Medical Management
Current Psychopharmacology Antipsychotics in Obsessive-Compulsive Disorder
Current Psychiatry Reviews Drug Therapy for Behavioral and Psychological Symptoms of Dementia
Current Neuropharmacology <i>Drosophila melanogaster</i> a Versatile Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Aggregation State and Neurotoxic Properties of Alzheimer β-Amyloid Peptide
Current Protein & Peptide Science Cyclic AMP-Specific Phosphodiesterase-4 as a Target for the Development of Antidepressant Drugs
Current Pharmaceutical Design Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges
Current Neuropharmacology Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and LDopa Treatment
Current Genomics